PT1268471E - Derivados n-heterociclicos como inibidores de nos - Google Patents

Derivados n-heterociclicos como inibidores de nos

Info

Publication number
PT1268471E
PT1268471E PT01918958T PT01918958T PT1268471E PT 1268471 E PT1268471 E PT 1268471E PT 01918958 T PT01918958 T PT 01918958T PT 01918958 T PT01918958 T PT 01918958T PT 1268471 E PT1268471 E PT 1268471E
Authority
PT
Portugal
Prior art keywords
inhibitors
heterocyclic derivatives
compounds
nitric oxide
oxide synthase
Prior art date
Application number
PT01918958T
Other languages
English (en)
Portuguese (pt)
Inventor
David D Davey
Gary B Phillips
Eric Pham
Wei Xu
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of PT1268471E publication Critical patent/PT1268471E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT01918958T 2000-03-27 2001-03-26 Derivados n-heterociclicos como inibidores de nos PT1268471E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19216800P 2000-03-27 2000-03-27
US09/814,787 US6525051B2 (en) 2000-03-27 2001-03-22 N-heterocyclic derivatives as NOS inhibitors

Publications (1)

Publication Number Publication Date
PT1268471E true PT1268471E (pt) 2004-03-31

Family

ID=26887800

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01918958T PT1268471E (pt) 2000-03-27 2001-03-26 Derivados n-heterociclicos como inibidores de nos

Country Status (13)

Country Link
US (1) US6525051B2 (enExample)
EP (1) EP1268471B1 (enExample)
JP (1) JP2003528871A (enExample)
AT (1) ATE252097T1 (enExample)
AU (1) AU2001245972A1 (enExample)
DE (1) DE60101000T2 (enExample)
DK (1) DK1268471T3 (enExample)
ES (1) ES2208578T3 (enExample)
HK (1) HK1053834A1 (enExample)
NO (1) NO20024614L (enExample)
PT (1) PT1268471E (enExample)
TR (1) TR200302268T4 (enExample)
WO (1) WO2001072744A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
US7012098B2 (en) * 2001-03-23 2006-03-14 Pharmacia Corporation Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
CN100349876C (zh) * 2001-11-30 2007-11-21 辛塔医药品有限公司 嘧啶化合物
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP1795192A3 (en) * 2002-04-30 2008-05-07 Bayer Schering Pharma Aktiengesellschaft 1-(Pyridazin-3-yl)-imidazole derivatives as inhibitors of nitric oxide synthase (NOS)
US6982259B2 (en) * 2002-04-30 2006-01-03 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
IL166241A0 (en) * 2002-07-29 2006-01-15 Rigel Pharmaceuticals Inc Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
ATE458731T1 (de) 2002-12-20 2010-03-15 Pfizer Prod Inc Pyrimidin-derivate zur behandlung von anormalem zellwachstum
US20080058297A1 (en) * 2003-05-29 2008-03-06 Synta Pharmaceuticals Corp. Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss
RS53109B (sr) 2003-07-30 2014-06-30 Rigel Pharmaceuticals Inc. Jedinjenja 2,4 pirimidindiamina za upotrebu u tretmanu ili prevenciji autoimunih bolesti
JP2007537235A (ja) 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の治療用ピリミジン誘導体
EP1758887A1 (en) 2004-05-14 2007-03-07 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth
CA2566332A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
TW200612948A (en) * 2004-07-01 2006-05-01 Synta Pharmaceuticals Corp 2-substituted heteroaryl compounds
ES2380550T3 (es) * 2004-11-24 2012-05-16 Rigel Pharmaceuticals, Inc. Compuestos de espiro-2,4-pirimidindiamina y sus usos
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
AU2006204750C1 (en) * 2005-01-14 2012-11-01 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
NZ555947A (en) 2005-01-19 2010-11-26 Rigel Pharmaceuticals Inc Prodrugs of 2,4-pyrimidinediamine compounds and their uses
CA2604551A1 (en) * 2005-05-03 2007-03-08 Rigel Pharmaceuticals, Inc. Jak kinase inhibitors and their uses
WO2007039578A1 (en) * 2005-10-05 2007-04-12 Nycomed Gmbh Imidazolyl-substituted azabenzophenone compounds
JP4782239B2 (ja) 2007-04-18 2011-09-28 ファイザー・プロダクツ・インク 異常細胞増殖治療のためのスルホニルアミド誘導体
KR101617050B1 (ko) 2007-07-12 2016-05-02 케모센트릭스, 인크. 염증의 치료를 위한 ｃｃｒ2 조절물질로서 융합된 헤테로아릴 피리딜과 페닐 벤젠술폰아마이드
US8063058B2 (en) * 2008-04-16 2011-11-22 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
AU2009248923B2 (en) 2008-05-21 2015-01-29 Takeda Pharmaceutical Company Limited Phosphorous derivatives as kinase inhibitors
US9834518B2 (en) 2011-05-04 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
CA2856301C (en) 2011-11-23 2020-10-06 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN110177549A (zh) 2016-11-23 2019-08-27 坎莫森特里克斯公司 治疗局灶性节段性肾小球硬化的方法
US11098026B2 (en) * 2017-03-13 2021-08-24 Impetis Biosciences Limited Fused bicyclic compounds, compositions and applications thereof
SG11202002975YA (en) 2017-10-11 2020-04-29 Chemocentryx Inc Treatment of focal segmental glomerulosclerosis with ccr2 antagonists
KR102563834B1 (ko) * 2021-06-28 2023-08-04 순천대학교 산학협력단 세포자멸사를 유도하는 신규한 화합물 및 이를 포함하는 항암용 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6339875A (ja) 1986-08-05 1988-02-20 Nissin Food Prod Co Ltd ピリミジン誘導体
DE4118720A1 (de) 1991-06-07 1992-12-10 Bayer Ag Substituierte imidazolinylpyrimidine
WO1993017009A1 (fr) 1992-02-28 1993-09-02 Zenyaku Kogyo Kabushiki Kaisha DERIVE DE s-TRIAZINE ET REMEDE CONTRE DES MALADIES DEPENDENTES DE L'×STROGENE LE CONTENANT COMME INGREDIENT ACTIF
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
ES2114662T3 (es) 1993-08-26 1998-06-01 Ono Pharmaceutical Co Derivados de la 4-aminopirimidina.
US5426110A (en) 1993-10-06 1995-06-20 Eli Lilly And Company Pyrimidinyl-glutamic acid derivatives
US5629322A (en) 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase
WO1996014842A1 (en) 1994-11-15 1996-05-23 Merck & Co., Inc. Substituted heterocycles as inhibitors of nitric oxide synthase
DK0813525T3 (da) * 1995-03-10 2004-02-16 Berlex Lab Benzamidinderivater, deres fremstilling og anvendelse som antikoagulanter
DE19541146A1 (de) * 1995-10-25 1997-04-30 Schering Ag Imidazolderivate und deren Verwendung als Stickstoffmonoxid-Synthase-Inhibitoren
ZA977427B (en) 1996-09-04 1998-03-02 Dainippon Pharmaceutical Co 2,4-disubstituted pyrimidine derivative, process for preparing the same, and a pharmaceutical composition containing the same.
WO1998027108A2 (en) * 1996-12-16 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. New amide compounds and their use as nitric oxide synthase inhibitors
PL335235A1 (en) 1997-02-19 2000-04-10 Berlex Lab N-heterocyclic derivatives as nos inhibitors

Also Published As

Publication number Publication date
DE60101000D1 (de) 2003-11-20
US6525051B2 (en) 2003-02-25
HK1053834A1 (zh) 2003-11-07
ATE252097T1 (de) 2003-11-15
NO20024614L (no) 2002-11-26
DK1268471T3 (da) 2004-02-09
TR200302268T4 (tr) 2004-01-21
JP2003528871A (ja) 2003-09-30
US20020010190A1 (en) 2002-01-24
AU2001245972A1 (en) 2001-10-08
EP1268471A1 (en) 2003-01-02
ES2208578T3 (es) 2004-06-16
DE60101000T2 (de) 2004-07-29
EP1268471B1 (en) 2003-10-15
WO2001072744A1 (en) 2001-10-04
NO20024614D0 (no) 2002-09-26

Similar Documents

Publication Publication Date Title
PT1268471E (pt) Derivados n-heterociclicos como inibidores de nos
PT1206467E (pt) Derivados n-heterociclicos como inibidores de nos
ATE301653T1 (de) Pyrazolopyridine
DK0968206T3 (da) N-heterocykliske derivater som NOS-inhibitorer
WO2003095455A3 (en) Substituted pyrazolopyrimidines
AU2003228678A1 (en) 1-substituted imidazole derivatives as nos inhibitors
ATE300541T1 (de) Pyrazolopyridinderivate
WO2004100865A3 (en) New benzimidazole derivatives
IL173810A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
ATE274515T1 (de) Pyrazolopyridinderivate
WO2003080631A8 (en) Plasma carboxypeptidase b inhibitors
SE9904128D0 (sv) Novel compounds
IL173895A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
IL173809A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
WO2004093796A3 (en) Lactam derivatives and methods of their use
DE60014915D1 (de) Hypoxanthin- und thiohypxanthin-verbindungen
SE0004480D0 (sv) Novel compounds